Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
ViroMissile, Inc.
Barbara Ann Karmanos Cancer Institute
Fusion Pharmaceuticals Inc.
Jonsson Comprehensive Cancer Center
Xencor, Inc.
Provectus Pharmaceuticals
AbbVie
SWOG Cancer Research Network
Rigshospitalet, Denmark
University of Southern California
Merck Sharp & Dohme LLC
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Rutgers, The State University of New Jersey